Abstract:ABSTRACT Rosacea is a chronic inflammatory skin condition marked by facial erythema, telangiectasia, and acne-like eruptions, affecting millions worldwide. While antibiotics remain a common treatment, prolonged use has significant adverse effects and can lead to antibiotic resistance. This study evaluated the impact of combined probiotics and doxycycline treatment on rosacea, emphasizing the gut–skin axis. Sixty rosacea patients were randomly assigned to the probiotic, placebo, or control groups. After a 2-week doxycycline treatment, participants underwent a 3-month intervention with either a placebo, probiotic, or no further treatment. Clinical outcomes were assessed at baseline and after the 14-week intervention. Our results showed that probiotic administration improved facial skin conditions, alleviated inflammation, and reduced facial skin microbiota diversity while enhancing gut microbiota heterogeneity. Multivariate analysis identified microbial markers distinguishing the probiotic group from the control and placebo groups, and some markers were associated with skin health parameters. After the probiotic intervention, some facial skin-associated taxa, such as Aquabacterium sp., UBA4096 sp. 1, UBA4096 sp. 2, and Yimella indica , decreased in abundance. Additionally, the fecal microbiota of the probiotic group was enriched in specific gut microbes, including Streptococcus parasanguinis , Erysipelatoclostridium ramosum , and Coprobacillus cateniformis , while showing a reduced abundance of Bacteroides vulgatus . These changes were associated with reduced facial sebum levels and a lower physician’s global assessment score. Finally, fewer antibiotic resistance genes, particularly tetracycline resistance genes, were detected in the probiotic group compared with the control and placebo groups. Our study supports the existence of a gut–skin axis and the application of probiotics in managing rosacea. IMPORTANCE This research elucidates rosacea management with novel insights into probiotic use alongside doxycycline, showing dual benefits in symptom relief and inflammation reduction in patients. The study maps probiotic-induced shifts in gut and skin microbiota, underscoring microbial shifts correlating with skin health improvements. Crucially, it deciphers the gut–skin axis modulation by probiotics, proposing a method to curb antibiotic resistance in rosacea therapies. This study furnishes robust evidence for probiotics in rosacea, advancing our grasp of the gut–skin relationship.

Probiotics suppress LL37 generated rosacea-like skin inflammation by modulating the TLR2/MyD88/NF-κB signaling pathway

Effect of combined probiotics and doxycycline therapy on the gut–skin axis in rosacea

Dietary supplementation of n-3 PUFAs ameliorates LL37-induced rosacea-like skin inflammation via inhibition of TLR2/MyD88/NF-κB pathway

Potential Role of Probiotics in Ameliorating Psoriasis by Modulating Gut Microbiota in Imiquimod-Induced Psoriasis-Like Mice

Rosacea, microbiome and probiotics: the gut-skin axis

Prevention and alleviation of allergic rhinitis by oral administration of Lacticaseibacillus paracasei GOLDGUT-Lpc969

Role of the skin microbiota and intestinal microbiome in rosacea

Tranilast alleviates skin inflammation and fibrosis in rosacea-like mice induced by long-term exposure to LL-37

Supramolecular salicylic acid ameliorates rosacea-like eruptions by suppressing NLRP3-mediated inflammasome activation in mice

Lithocholic Acid Promotes Rosacea-Like Skin Inflammation Via G Protein-Coupled Bile Acid Receptor 1

Lactobacillus rhamnosus ameliorates acne vulgaris in SD rats via changes in gut microbiota and associated tryptophan metabolism

Anti-Inflammatory Effects of Novel Probiotic Lactobacillus Rhamnosus RL-H3-005 and Pedicoccus Acidilactici RP-H3-006: in Vivo and in Vitro Evidence

Gut and Cutaneous Microbiome Featuring Abundance of<i> Lactobacillus</i><i> reuteri</i> Protected Against Psoriasis-Like Inflammation in Mice

Targeting the STAT3/IL-36G Signaling Pathway Can Be a Promising Approach to Treat Rosacea

Lactobacillus Plantarum AR113 Alleviates DSS-induced Colitis by Regulating the TLR4/MyD88/NF-κB Pathway and Gut Microbiota Composition

Protective effects of a novel Lactobacillus rhamnosus strain with probiotic characteristics against lipopolysaccharide-induced intestinal inflammation in vitro and in vivo.

Causal relationship between gut microbiota and rosacea: a two-sample Mendelian randomization study

Integrated Omics Reveal the Molecular Characterization and Pathogenic Mechanism of Rosacea.

Antioxidant strain Lactiplantibacillus plantarum AS21 and Clostridium butyricum ameliorate DSS-induced colitis in mice by remodeling the assembly of intestinal microbiota and improving gut functions

Gut and Cutaneous Microbiome Featuring Abundance of Lactobacillus reuteri Protected Against Psoriasis-Like Inflammation in Mice

Therapeutic Potential of the Probiotic Lactiplantibacillus Plantarum BX 62 and Its Postbiotics in Alleviating Rheumatoid Arthritis in Mice